<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400231</url>
  </required_header>
  <id_info>
    <org_study_id>800860</org_study_id>
    <nct_id>NCT00400231</nct_id>
  </id_info>
  <brief_title>The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study</brief_title>
  <official_title>The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      Patients with metabolic syndrome, insulin resistance, and elevated triglycerides of 150 mg/dl&#xD;
      or higher will be randomized to one of four groups: 1) placebo; 2) metformin; 3) fenofibrate;&#xD;
      or 4) combined metformin and fenofibrate for a period of 12 weeks after titration to target&#xD;
      dose. We are interested in the effects of these therapies on triglyceride levels, HDL-C,&#xD;
      insulin resistance, and markers of inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>triglyceride levels</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-C, Resistin, insulin resistance</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Metabolic Syndrome x</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate and Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study drugs: Metformin and fenofibrate</intervention_name>
    <description>145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Drug: Metformin</intervention_name>
    <description>2000mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study Drug: fenofibrate</intervention_name>
    <description>145mg/day of fenofibrate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Fenofibrate placebo</intervention_name>
    <description>placebo metformin and fenofibrate</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects between the ages of 18 and 75 with both of the following risk factors:&#xD;
&#xD;
          1. Fasting triglycerides &gt;= 150 mg/dl (but less than 800 mg/dl)&#xD;
&#xD;
          2. Glucose of 140 to 199 mg/dl, 2 hours after a 75 gm oral glucose load, a fasting HOMA&#xD;
             level in the upper quartile (&gt; 2.68), or a plasma triglyceride to high density&#xD;
             lipoprotein cholesterol concentration &gt; 3.0&#xD;
&#xD;
        And at least one of the following three:&#xD;
&#xD;
          1. Central obesity (waist size &gt; 40 inches in men or &gt;35 inches in women)&#xD;
&#xD;
          2. A systolic blood Pressure of &gt;130 mmHg and/or a diastolic blood pressure of &gt;85 mmHg&#xD;
             and/or taking an antihypertensive medication.&#xD;
&#xD;
          3. HDL &lt; 40 mg/dl for men or &lt; 50 mg/dl for women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood pressure &gt; 180/95 mmHg (subjects may be re-screened after adequate blood&#xD;
             pressure control has been obtained)&#xD;
&#xD;
          2. Women who are pregnant or lactating, or who are of child-bearing potential and not&#xD;
             using an acceptable method of birth control.&#xD;
&#xD;
          3. Chronic renal insufficiency (serum creatinine &gt;1.5 mg/dl in men and &gt; 1.4 mg/dl in&#xD;
             women&#xD;
&#xD;
          4. Any active liver disease or abnormal LFTs (&gt;2x upper limit normal)(12)&#xD;
&#xD;
          5. Active infection, malignancy or chronic inflammatory disorder&#xD;
&#xD;
          6. Concomitant use of niacin, a bile acid sequestrant, or ezetimibe. If it is deemed safe&#xD;
             by the patient's primary physician and by the principal investigator, patients may be&#xD;
             screened for enrollment upon stopping these medications for at least 2 weeks.&#xD;
&#xD;
          7. Subjects on statins will need to be on less than maximal dose (e.g. &lt; 80 mg per day&#xD;
             for simvastatin or atorvastatin). Subjects will also need to have been on a stable&#xD;
             dose of statin therapy for at least 1 month prior to enrollment and continue their&#xD;
             currently prescribed statin at the same dose throughout the study. If it is deemed&#xD;
             safe by the patient's primary physician and by the principal investigator, patients on&#xD;
             maximal statin therapy (usually 80 mg/day) may reduce their dose of statin therapy to&#xD;
             a sub maximal dose (usually 40 mg/day) for 4 weeks prior to screening for enrollment.&#xD;
&#xD;
          8. History of lactic acidosis(12)&#xD;
&#xD;
          9. Expected need for use of intravenous radiographic contrast during the study&#xD;
&#xD;
         10. More than moderate alcohol use (&gt; 14 drinks per week)&#xD;
&#xD;
         11. Moderate to severe left ventricular dysfunction (ejection fraction &lt;45%)&#xD;
&#xD;
         12. Decompensated heart failure or decompensated lung disease that has resulted in hypoxia&#xD;
             or reduced peripheral perfusion within the past year regardless of left ventricular&#xD;
             ejection fraction (thus patients with underlying heart disease, coronary artery&#xD;
             disease, mild left ventricular dysfunction (ejection fraction &gt; 45%), or lung disease&#xD;
             that has been stable for at least one year will be eligible to participate)&#xD;
&#xD;
         13. Creatinine kinase (CK) levels â‰¥ 2.5 ULN or history of statin-induced myopathy.&#xD;
             Patients with a CK level more than 2.5 times the upper limit of normal may undergo&#xD;
             repeat testing up to two more times before being excluded (since vigorous physical&#xD;
             activity can often elevate CK levels, and this would not increase the risk of&#xD;
             myopathy).&#xD;
&#xD;
         14. Participation in an investigational drug study within 6 weeks prior to the screening&#xD;
             visit&#xD;
&#xD;
         15. Surgery within the previous 30 days&#xD;
&#xD;
         16. Concomitant use of ketoconazole, itraconazole, cyclosporin A, erythromycin, or&#xD;
             Clarithromycin.&#xD;
&#xD;
         17. Hemoglobin &lt; 10 mg/dl, active use of coumadin, history of bleeding disorder, or&#xD;
             abnormal clotting time (protime &gt;14.6 seconds and aPTT &gt; 37.0)&#xD;
&#xD;
         18. Septic shock&#xD;
&#xD;
         19. Acute coronary syndrome or stroke within 3 months prior to study&#xD;
&#xD;
         20. Serious or unstable medical or psychological conditions that, in the opinion of the&#xD;
             investigator, would compromise the subject's safety or successful participation in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick F. Samaha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>inflammation</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Elevated triglycerides</keyword>
  <keyword>without diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

